がん治療における世界のゲノミクス市場の規模は2023年に181億2000万ドルと評価され、2024年から2030年にかけて16.0%のCAGRで成長すると予測されています。市場成長の主な要因は、がん症例の増加と個別化治療の需要の高まりです。WHOによると、2022年には新たに2,000万人のがん患者が報告され、970万人が死亡しました。さらに、技術革新、投資の増加、研究開発活動の増加、シーケンシングコストの低下も、市場の成長を促進する要因です。
目次
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Genomic in Cancer Care Market Variables, Trends, & Scope
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Genomic in Cancer Care Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
Chapter 4. Genomics in Cancer Care Market: Product Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Genomics in Cancer Care Market: Product Movement Analysis, 2023 & 2030 (USD Million)
4.3. Instruments
4.3.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Consumables
4.4.1. Consumables Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Services
4.5.1. Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Genomics in Cancer Care Market: Application Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Genomics in Cancer Care Market: Application Movement Analysis, 2023 & 2030 (USD Million)
5.3. Diagnostics
5.3.1. Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Personalized Medicine
5.4.1. Personalized Medicine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Drug Discovery & Development
5.5.1. Drug Discovery & Development Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Research
5.6.1. Research Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Genomics in Cancer Care Market: Technology Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Genomics in Cancer Care Market: Technology Movement Analysis, 2023 & 2030 (USD Million)
6.3. Genome Sequencing
6.3.1. Genome Sequencing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. PCR
6.4.1. PCR Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Microarrays
6.5.1. Microarrays Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Nucleic Acid Extraction & Purification
6.6.1. Nucleic Acid Extraction & Purification Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7. Other
6.7.1. Other Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Genomics in Cancer Care Market: Regional Estimates & Trend Analysis
7.1. Genomics in Cancer Care Market Share, By Region, 2023 & 2030 (USD Million)
7.2. North America
7.2.1. North America Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. U.S. Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.3. Canada
7.2.3.1. Canada Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.4. Mexico
7.2.4.1. Mexico Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3. Europe
7.3.1. Europe Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.2. U.K.
7.3.2.1. U.K. Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Germany Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.4. France
7.3.4.1. France Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.2. China
7.4.2.1. China Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.3. Japan
7.4.3.1. Japan Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.4. India
7.4.4.1. India Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.5. South Korea
7.4.5.1. South Korea Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.6. Australia
7.4.6.1. Australia Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Latin America
7.5.1. Latin America Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Brazil Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Middle East and Africa
7.6.1. Middle East and Africa Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.2. Saudi Arabia
7.6.2.1. Saudi Arabia Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.3. UAE
7.6.3.1. UAE Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.4. South Africa
7.6.4.1. South Africa Genomics in Cancer Care Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
8.4.1. Agilent Technologies, Inc.,
8.4.1.1. Participant’s Overview
8.4.1.2. Financial Performance
8.4.1.3. Product Benchmarking
8.4.1.4. Recent Developments/ Strategic Initiatives
8.4.2. F. Hoffmann-La Roche Ltd
8.4.2.1. Participant’s Overview
8.4.2.2. Financial Performance
8.4.2.3. Product Benchmarking
8.4.2.4. Recent Developments/ Strategic Initiatives
8.4.3. Beckman Coulter, Inc.,
8.4.3.1. Participant’s Overview
8.4.3.2. Financial Performance
8.4.3.3. Product Benchmarking
8.4.3.4. Recent Developments/ Strategic Initiatives
8.4.4. Illumina Inc.
8.4.4.1. Participant’s Overview
8.4.4.2. Financial Performance
8.4.4.3. Product Benchmarking
8.4.4.4. Recent Developments/ Strategic Initiatives
8.4.5. Abbott
8.4.5.1. Participant’s Overview
8.4.5.2. Financial Performance
8.4.5.3. Product Benchmarking
8.4.5.4. Recent Developments/ Strategic Initiatives
8.4.6. Cancer Genetics Inc.
8.4.6.1. Participant’s Overview
8.4.6.2. Financial Performance
8.4.6.3. Product Benchmarking
8.4.6.4. Recent Developments/ Strategic Initiatives
8.4.7. Bio-Rad Laboratories
8.4.7.1. Participant’s Overview
8.4.7.2. Financial Performance
8.4.7.3. Product Benchmarking
8.4.7.4. Recent Developments/ Strategic Initiatives
8.4.8. PacBio
8.4.8.1. Participant’s Overview
8.4.8.2. Financial Performance
8.4.8.3. Product Benchmarking
8.4.8.4. Recent Developments/ Strategic Initiatives
8.4.9. GE Healthcare
8.4.9.1. Participant’s Overview
8.4.9.2. Financial Performance
8.4.9.3. Product Benchmarking
8.4.9.4. Recent Developments/ Strategic Initiatives
8.4.10. Quest Diagnostics Incorporated
8.4.10.1. Participant’s Overview
8.4.10.2. Financial Performance
8.4.10.3. Product Benchmarking
8.4.10.4. Recent Developments/ Strategic Initiatives
8.4.11. PerkinElmer
8.4.11.1. Participant’s Overview
8.4.11.2. Financial Performance
8.4.11.3. Product Benchmarking
8.4.11.4. Recent Developments/ Strategic Initiatives
8.4.12. Luminex
8.4.12.1. Participant’s Overview
8.4.12.2. Financial Performance
8.4.12.3. Product Benchmarking
8.4.12.4. Recent Developments/ Strategic Initiatives
